EPA New Chemicals data shows submitter-side delays hold up market entry

What the data shows

EPA's New Chemicals Program status pages continue to show two categories that matter to industry:

• Cases in active risk assessment at EPA, and
• Cases awaiting the submitter's signature on a consent order or other instrument.

The second category is the one companies can control. When a case waits on the submitter, the delay is internal, not regulatory.

Why this matters

A new-chemical clearance is on the critical path to a US launch. It is slowed by things that are firmly on the company's side of the line:

• Exposure and release information that is incomplete or inconsistent when the notice is filed, prompting EPA questions
• Unresolved exposure scenarios for downstream or consumer uses
• Slow order-signature workflows — a consent order that sits unsigned while approvals route through EHS and legal

Recommended actions

• Run a PMN / SNUN / MCAN dashboard with the status and next action for every open case.
• Make exposure-data readiness a gate before filing: uses, volumes, release points and worker/consumer exposure defined and defensible.
• Set an order-signature escalation path with a target turnaround measured in days.
• Require an EHS review before signing a consent order, so conditions are understood before they are accepted.
• After approval, apply the resulting use conditions in ERP and in customer-facing controls, so the product is not sold outside the cleared scope.